Thomas Jonathan Stewart1,2, Alan Saunders3. 1. a Darlinghurst Medical Centre , Darlinghurst , New South Wales , Australia. 2. b School of Medicine , University of New South Wales , Sydney Australia. 3. c Caringbah Medical and Dental Centre , Caringbah , New South Wales , Australia.
Abstract
BACKGROUND AND OBJECTIVES: The standard treatment for cutaneous squamous cell carcinoma (cSCC) is wide local excision (WLE). Incomplete tumor excision is associated with increased recurrence rates and mortality risk. Risk factors for positive margins after WLE of cSCC has been examined in only a few studies. We sought to assess the influence of several clinicopathological factors on margin status in the largest cSCC population to date. METHODS: We performed a retrospective review of records at two skin cancer clinics identifying patients with biopsy-proven cSCC who underwent WLE. We mined clinicopathological information for eligible subjects including age, gender, lesion location, immunosuppression, previous treatment, lesion size, biopsy type, tumor subtype, tumor thickness, degree of differentiation, ulceration and perineural invasion. RESULTS: A total of 1468 patients were eligible and 117 (8%) had positive margins after WLE. Older age at diagnosis (p = .011), lesion location on the head and neck (p < .001), previous treatment (p < .001), increased lesion diameter (p < .001), invasive subtype (p = .020) or increased tumor thickness (p < .001) were statistically significant risk factors for positive surgical margins. CONCLUSIONS: Our results present an opportunity to stratify cSCC patients into low- or high-risk for incomplete tumor clearance after WLE based on several clinicopathological factors. These findings should educate and inform the dermatologic surgeon's choice of primary management of cSCC.
BACKGROUND AND OBJECTIVES: The standard treatment for cutaneous squamous cell carcinoma (cSCC) is wide local excision (WLE). Incomplete tumor excision is associated with increased recurrence rates and mortality risk. Risk factors for positive margins after WLE of cSCC has been examined in only a few studies. We sought to assess the influence of several clinicopathological factors on margin status in the largest cSCC population to date. METHODS: We performed a retrospective review of records at two skin cancer clinics identifying patients with biopsy-proven cSCC who underwent WLE. We mined clinicopathological information for eligible subjects including age, gender, lesion location, immunosuppression, previous treatment, lesion size, biopsy type, tumor subtype, tumor thickness, degree of differentiation, ulceration and perineural invasion. RESULTS: A total of 1468 patients were eligible and 117 (8%) had positive margins after WLE. Older age at diagnosis (p = .011), lesion location on the head and neck (p < .001), previous treatment (p < .001), increased lesion diameter (p < .001), invasive subtype (p = .020) or increased tumor thickness (p < .001) were statistically significant risk factors for positive surgical margins. CONCLUSIONS: Our results present an opportunity to stratify cSCC patients into low- or high-risk for incomplete tumor clearance after WLE based on several clinicopathological factors. These findings should educate and inform the dermatologic surgeon's choice of primary management of cSCC.
Authors: Evi M Morandi; Tina Rauchenwald; Petra Puelzl; Bernhard W Zelger; Bettina G Zelger; Benjamin Henninger; Gerhard Pierer; Dolores Wolfram Journal: J Dtsch Dermatol Ges Date: 2021-11 Impact factor: 5.231
Authors: Roel E Genders; Nick Marsidi; Marlies Michi; Erik P Henny; Jelle J Goeman; Marloes S van Kester Journal: Acta Derm Venereol Date: 2020-03-18 Impact factor: 3.875
Authors: Manuel António Campos; Sofia Macedo; Margarida Sá Fernandes; Ana Pestana; Joana Pardal; Rui Batista; João Vinagre; Agostinho Sanches; Armando Baptista; José Manuel Lopes; Paula Soares Journal: Genes (Basel) Date: 2020-07-06 Impact factor: 4.096
Authors: N Marsidi; R Ottevanger; J N Bouwes Bavinck; N M A Krekel-Taminiau; J J Goeman; R E Genders Journal: J Eur Acad Dermatol Venereol Date: 2022-04-20 Impact factor: 9.228